https://www.polity.org.za
Deepening Democracy through Access to Information
Home / News / African News RSS ← Back
Health|Safety|Systems
Health|Safety|Systems
health|safety|systems
Close

Email this article

separate emails by commas, maximum limit of 4 addresses

Sponsored by

Close

Article Enquiry

WHO approves Bavarian Nordic's mpox vaccine for adolescents

Close

Embed Video

WHO approves Bavarian Nordic's mpox vaccine for adolescents

Mpox virus test tubes
Photo by Reuters

14th October 2024

By: Reuters

SAVE THIS ARTICLE      EMAIL THIS ARTICLE

Font size: -+

The World Health Organization (WHO) said on Monday it had approved Bavarian Nordic's mpox vaccine for adolescents aged 12 to 17 years, an age group considered especially vulnerable to outbreaks of the disease that has triggered global concern.

The WHO said in a statement that it gave the Jynneos vaccine prequalification for adolescents on October 8.

Advertisement

The WHO declared mpox a global public health emergency for the second time in two years in August after a new type of the virus spread from the Democratic Republic of Congo to its neighbours.

The United Nations agency approved the use of the vaccine in September as the first shot against mpox in adults, making it easier for badly hit African countries to access the vaccine.

Advertisement

Children, adolescents and those with weakened immune systems have been particularly vulnerable to mpox, a viral infection that typically causes flu-like symptoms and skin lesions filled with pus.

WHO's latest decision comes after the EU approved the drug for the vaccine for adolescents in September.

The Danish biotech firm is also preparing to conduct a clinical trial to assess the vaccine's safety in children aged two to 12, potentially extending its use.

The trial, partially funded by the Coalition for Epidemic Preparedness Innovations, is expected to start in October.

The US Food and Drug Administration has also approved Bavarian's shot, but only for use in adults 18 years and older, although it granted Emergency Use Authorization for its use in adolescents during the mpox outbreak of 2022.

Another mpox vaccine, LC16, made by Japan's KM Biologics, can already be given to children, according to the Japanese regulator, although it requires a special kind of needle.

Bavarian Nordic did not immediately respond to a request for comment on the prequalification.

EMAIL THIS ARTICLE      SAVE THIS ARTICLE

To subscribe email subscriptions@creamermedia.co.za or click here
To advertise email advertising@creamermedia.co.za or click here

Comment Guidelines

About

Polity.org.za is a product of Creamer Media.
www.creamermedia.co.za

Other Creamer Media Products include:
Engineering News
Mining Weekly
Research Channel Africa

Read more

Subscriptions

We offer a variety of subscriptions to our Magazine, Website, PDF Reports and our photo library.

Subscriptions are available via the Creamer Media Store.

View store

Advertise

Advertising on Polity.org.za is an effective way to build and consolidate a company's profile among clients and prospective clients. Email advertising@creamermedia.co.za

View options

Email Registration Success

Thank you, you have successfully subscribed to one or more of Creamer Media’s email newsletters. You should start receiving the email newsletters in due course.

Our email newsletters may land in your junk or spam folder. To prevent this, kindly add newsletters@creamermedia.co.za to your address book or safe sender list. If you experience any issues with the receipt of our email newsletters, please email subscriptions@creamermedia.co.za